Haleon plc (HLN) Stock Price

Haleon plc Price

NYSE·CLOSED
10.05
​
Market closed

Over the last 6 years Haleon plc grew revenue by 4.1% annually, reaching 10.79 B USD. Earnings per share have grown at 17.0% per year over the last 6 years. For Haleon plc, the net margin of 15.1% is broadly stable versus 14.6% a few years ago. The consensus 12-month price target for Haleon plc is 10.20 USD, about 1.5% above where the stock trades today. Of 26 analysts, 19 rate the stock a buy — an overall Buy consensus.

Haleon plc stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Haleon plc business model & stock analysis

Haleon plc, headquartered in Weybridge, United Kingdom, operates in the Health Care sector, focusing on consumer healthcare products. The company develops and sells oral health products like Sensodyne and Parodontax, vitamins under Centrum, and OTC remedies including Theraflu and Voltaren across North America, Europe, the Middle East, Africa, Latin America, and Asia Pacific. Listed on 22 July 2022, Haleon was formerly DRVW 2022 plc and changed its name in February 2022. Founded in 1715, it employs over 10,000 people globally.

Frequently asked questions about Haleon plc

Analysts currently set an average price target of 10.20 USD for the Haleon plc stock (median: 10.20 USD), implying +1.5 % versus the latest price. The consensus is based on 26 analyst ratings.

26 analysts currently rate the Haleon plc stock: 19 recommend buying, 5 holding and 2 selling. For 2026, analysts expect Haleon plc to generate revenue of 15.05 B USD and earnings per share of 0.55 USD.

Converted at the current exchange rate, the Haleon plc share trades at 8.95 EUR (10.05 USD).

The expected revenue of Haleon plc is 15.05 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Haleon plc is 2.46 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Haleon plc is currently 18.28. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Haleon plc stock.

The price-to-sales ratio (P/S) of Haleon plc is currently 2.99. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Haleon plc stock.

The Eulerpool Quality Score for Haleon plc is 3/10.

The ISIN of Haleon plc is US4055521003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Haleon plc is HLN. The ticker symbol is used to trade Haleon plc shares on the stock exchange.

Fair ValueTerminal
9.44 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
1.04 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website haleon.com
Currency
USD
Initial public offering
Jul 22, 2022
ISIN
US4055521003
Cusip
405552100
Market capitalization
44.35 B USDLarge Cap
52-Week Range
PEG
6.54
P/E ratio
P/Ee 2026
18.01
P/Ee 2027
16.56
P/Ee 2028
15.34
P/Ee 2029
14.69
P/Ee 2030
14.64
P/S
P/Se
2.99
EV/EBIT
21.35
P/B Ratio
2.70
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
6.51 %
Last updated Oct 19, 2026, 12:57 PM

Haleon plc Peer Group

All fundamentals and in-depth analysis of Haleon plc

Our stock analysis for Haleon plc stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Haleon plc. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.